Nuevo test de covid-19 basado en inteligencia artificial llega a Lambra de la mano de Virusight Diag
La empresa de Virusight Diagnostic ha publicado su solución basada en Inteligencia Artificial que ha demostrado una gran correlación con el PCR. Las pruebas se han realizado ya en los hospitales del área de Madrid, Castilla-La-Mancha y Castilla-León incluyendo pruebas de muestras infectadas y no infectadas tomadas antes del PCR.
La solución de Virusight instantánea es capaz de comprobar si una muestra esta infectada o no de COVID-19 en tan solo un segundo, basándose en la Inteligencia Artificial usando un método espectro grafico de absorción. Además, Virusight ya tiene 26 test piloto activos alrededor del mundo entre distintos hospitales de Europa y próximamente en Asia pacifico. Esta compañía ya ha firmado con Lambra, para traer los primeros test de Inteligencia Artificial a España y distribuirlos entre sus clientes.
“Nuestro objetivo es traer esta solución revolucionaria al mercado, así que nos estamos sumergiendo en las pruebas piloto con la tecnología del producto SpectraLIT, el cual garantiza resultados del COVID-19 fiables en segundos usando muestras de hisopos de los pacientes o sus muestras de saliva”, es lo que dice Yaron Navon, el dueño y director de Lambra, ante este producto de vanguardia que tanto puede ayudar a reducir la curva de contagios de forma rápida y eficaz.
La empresa de Virusight está en un gran momento de avance, ya que sus tests a través de sus colaboradores como Lambra, han demostrado ser exitosos y podrán permitir test masivos para todos y ayudar a controlar la pandemia.
Virusight Diagnostic’s solution for instant COVID-19 screening demonstrates high correlation to PCR in pre-clinical testing in Spain and company signs an MOU for 50 million tests in APAC
Virusight Diagnostic, A JV of Newsight Imaging and Sheba Medical Center with 26 active pilots in leading hospitals around the world, files for regulation approvals Ramat Gan, Israel, November 12, 2020, Virusight Diagnostic, a newly formed AI healthcare JV of Sheba Medical Center and Newsight Imaging, reported today that its AI solution for a COVID-19 1-second test, has demonstrated excellent correlation to PCR. The pre-clinical testing has been performed by Microbiology and Molecular departments at leading hospitals in area of Madrid, Castilla-La Mancha and Castilla -León regions and included hundreds of real swab samples of COVID-19 infected and non-infected patients, taken before PCR. In this initial test, Virusight Diagnostic's solution demonstrated a very high correlation to PCR while testing 130 non-labeled samples out of a total 330 samples. Virusight's instant screening solution is based on licensing of Newsight Imaging's SpectraLIT™ - a game changing spectral device, together with a special AI software. The device is capable of checking a swab's UTM liquid, or mouthwash, in only one second, using an absorbance spectrographic method. The company has signed an agreement with Lambra ,which specializes in marketing medical products in Spain, led by Mr. Yaron Navon to perform pilots in Spain and distribute its solution to Lambra's customers. Virusight currently has 26 active pilots with leading hospitals around the world, aiming to achieve local validation of its technology, parallel to its efforts to obtain regulation approvals. The pilots are conducted in collaboration with local partners, such as Lambra, and AI Innobio, the company’s partner for the Asia Pacific region. Alongside European countries and other areas worldwide, Virusight has already secured its distribution in Asia Pacific, signing an MOU with AI Innobio to sell 50 million tests to APAC countries to be used within one year. Yaron Navon, Owner and Managing Director of Lambra " We are focused on the commercialization of products designed to fight against COVID-19. So far, we offered Rapid tests for anti-bodies and antigens. Our goal is to bring this revolutionary solution to the market, so we are currently immersing ourselves in pilot trial runs with the SpectraLIT™ product which guarantees reliable COVID-19 results in seconds using patient’s swab or mouthwash sample". The Chairman and acting CEO of AI InnoBio Dr. George So: “I am so excited to bring the SpectraLIT™ technology to the APAC region. AI InnoBio has signed MOU with partners in eight countries in this region to introduce the “FAIR” AIIB SpectraLIT™ COVID-19 quick test solution for the current pandemic. We will soon start pilot studies in 5 countries including India, Philippines, South Korea, Singapore, etc. AIIB SpectraLIT™ is "FAIR" because the technology is Fast, Affordable , Innovative and Reliable. This quick test can be used as a screening device between countries to safeguard travel bubbles and kick start economy recovery in the APAC region”. Eli Assoolin, Board Chairman and Acting CEO of Virusight Diagnostic added: "Virusight is in a great momentum forward. Our solid concept of "validation before business" proved to be successful and attractive for our selected partners, such as Lambra and AI Innobio. Virusight Diagnostic’s solution, powered by Newsight Imaging’s technology and Sheba Medical Center’s excellence, is about to enable affordable mass screening checks for everyone, and help the world resume normal life. We are very excited to be a part of this important goal".
